Please login to the form below

Not currently logged in
Email:
Password:

ALK inhibitor

This page shows the latest ALK inhibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer claims rapid FDA nod for Lorbrena

Pfizer claims rapid FDA nod for Lorbrena

The FDA has granted approval to Pfizer's next generation ALK inhibitor lung cancer treatment Lorbrena, which will help it defend its presence in the market. ... Follow-up ALK inhibitors are important in this treatment pathway, as many experience tumour

Latest news

  • Pfizer’s flat sales focus investor attention on M&A Pfizer’s flat sales focus investor attention on M&A

    Among the highlights cited by Read on the call were oncology drugs talazoparib - a PARP inhibitor due for filing shortly for breast cancer - along with ALK/ROS1 inhibitor lorlatinib and EGFR ... inhibitor dacomitinib for lung cancer, which are due for

  • Pfizer files third-gen ALK inhibitor for lung cancer Pfizer files third-gen ALK inhibitor for lung cancer

    Pfizer has filed for approval of its third-generation ALK inhibitor lorlatinib, a follow-up to its first-generation Xalkori product which is facing increasing competition. ... Lorlatinib was developed by Pfizer scientists with the specific goal of

  • Roche gets FDA OKs for Alecensa and Zelboraf Roche gets FDA OKs for Alecensa and Zelboraf

    Roche’s oncology business unit chalked up two FDA approvals this week for its new ALK inhibitor Alecensa in first-line lung cancer and BRAF inhibitor Zelboraf in a rare blood ... That allows Roche’s drug to take on Pfizer’s drug - as well as

  • Novartis gets first-line approval for Xalkori challenger in EU Novartis gets first-line approval for Xalkori challenger in EU

    Novartis' Zykadia can now compete head-to-head in Europe against Pfizer's Xalkori after winning approval as a first-line therapy for ALK-positive non-small cell lung cancer (NSCLC). ... It is only the second ALK inhibitor approved for first-line use in

  • Novartis' Zykadia claims US approval for first-line lung cancer Novartis' Zykadia claims US approval for first-line lung cancer

    The approval is good news for Novartis, although its key competitor in the coming period will not be so much Xalkori as Roche's ALK inhibitor Alecensa (alectinib), which bested ... Meanwhile additional competition in the ALK inhibitor market is looming

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics